Treatment with Sanofi Genzyme’s Lemtrada (alemtuzumab) for up to two years lowers the levels of serum neurofilament light chain (sNfL), a proposed biomarker of nerve damage, in relapsing-remitting multiple sclerosis (RRMS) patients to levels comparable to those seen in healthy people, data from the CARE-MS I study shows.
These results were shared in the presentation “Alemtuzumab Treatment Reduces Serum Neurofilament to Levels Comparable With Healthy Controls More Effectively Than SC IFNb-1a: CARE-MS I” at the recent 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) in Seattle, Washington.
In the CARE-MS I (NCT00530348) trial, RRMS patients with highly active disease, 18 to 53 years old, were randomized to begin treatment with either 12 mg of Lemtrada, infused for three or five consecutive days in two annual courses, or with subcutaneous (under-the-skin) injections of Rebif given three times weekly for two years. The safety and efficacy of the two treatments were compared at the study’s end in 2011.
Data showed that Lemtrada reduced disease activity over two years significantly more than did Rebif.
Now researchers assessed the effects of Lemtrada against Rebif based on blood levels of sNfL, a proposed biomarker of nerve cell damage and disease activity, in CARE-MS I trial participants.
Their sNfL levels were compared to those of healthy controls, after being adjusted for participants’ age.
Results showed that the median levels of sNfL in healthy controls ranged from 12.0 pg/mL at 18 years old to 27.1 pg/mL at age 53.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?